Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;31(3):264-8.
doi: 10.1097/MOG.0000000000000171.

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

Mitesh J Borad  1 , Gregory J Gores, Lewis R Roberts
Affiliations
Review

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

Mitesh J Borad et al. Curr Opin Gastroenterol. 2015 May.

Abstract

Purpose of review: This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA).

Recent findings: Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.

Summary: Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.

Trial registration: ClinicalTrials.gov NCT02150967 NCT02265341.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

References

    1. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–2179. - PMC - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. - PubMed
    1. Chan-On W, Nairismägi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and noninfection-related bile duct cancers. Nat Genet. 2013;45:1474–1478. - PubMed
    1. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470–1473. - PMC - PubMed
    1. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–693. - PubMed

MeSH terms

Associated data